Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy-Reference-Cited by-同舟云学术

Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy

Published:2013-01-07 Issue:8 Volume:22 Page:810-818
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Mack Christina DeFilippo¹,Glynn Robert J.²,Brookhart M. Alan¹,Carpenter William R.³⁴,Meyer Anne Marie⁴,Sandler Robert S.⁵,Stürmer‎ Til¹

Affiliation:

1. Department of Epidemiology; UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill; Chapel Hill NC USA

2. Division of Pharmacoepidemiology and Pharmacoeconomics; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Boston MA USA

3. Department of Health Policy and Management; Gillings School of Global Public Health UNC; Chapel Hill NC USA

4. Lineberger Comprehensive Cancer Center and Cecil G. Sheps Center for Health Services Research; University of North Carolina; Chapel Hill NC USA

5. Division of Gastroenterology and Hepatology; University of North Carolina; Chapel Hill NC USA

Funder

National Institute on Aging

National Cancer Institute

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.3386/fullpdf

Reference46 articles.

1. The Central Role of the Propensity Score in Observational Studies for Causal Effects;Rosenbaum;Biometrika,1983

2. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly;Stürmer;Am J Epidemiol,2005

3. Estimating causal effects from large data sets using propensity scores;Rubin;Ann Intern Med,1997

4. National Cancer Institute Highlights from ASCO 2003 2003 http://www.cancer.gov/asco2003/highlights

5. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;André;N Engl J Med,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Sodium Glucose Cotransporter‐2 Inhibitors on Hemoglobin A1c Variability and Acute Kidney Injury: A Causal Mediation Analysis;Pharmacoepidemiology and Drug Safety;2024-08

2. Risk of abnormal uterine bleeding associated with high-affinity compared with low-affinity serotonin and norepinephrine reuptake inhibitors;Journal of Affective Disorders;2024-04

3. Doubly robust estimation of optimal treatment regimes for survival data using an instrumental variable;Statistics and Computing;2024-03-16

4. Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study;Journal of the American Academy of Dermatology;2023-08

5. Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System;Clinical Epidemiology;2023-05